tirzepatide compound lawsuit update FDA Says Compounded Must Exit the Market Important Update: Compounded Tirzepatide Phasing

If you notice persistent irritation, redness, or any unusual reactions, discontinue use and consult a dermatologist

When a new prescription drug enters the market, the question for employers isnt just does it work? Its what does covering it mean for our people, our plan, and our longterm costs? That question became especially relevant in early 2026, when an oral version of Wegovy entered the market with widespread media coverage

GHRP Pathway (Ipamorelin) Ipamorelin selectively stimulates the ghrelin receptor to release growth hormone without raising cortisol, prolactin, or hunger its key clinical advantage over older GHRPs

So, heres what the research shows